Disease Modification in Multiple Sclerosis by Flupirtine—Results of a Randomized Placebo Controlled Phase II Trial

Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprote...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Front Neurol
Egile Nagusiak: Dörr, Jan, Wernecke, Klaus-Dieter, Würfel, Jens, Bellmann-Strobl, Judith, Siffrin, Volker, Sättler, Muriel B., Simons, Mikael, Linsa, Andreas, Tumani, Hayrettin, Paul, Friedemann
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Frontiers Media S.A. 2018
Gaiak:
Neurology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6190842/
https://ncbi.nlm.nih.gov/pubmed/30356868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2018.00842
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak